JP2024516998A - Ｓｈｐ２阻害剤とｅｇｆｒチロシンキナーゼ阻害剤とを含む併用療法 - Google Patents

Ｓｈｐ２阻害剤とｅｇｆｒチロシンキナーゼ阻害剤とを含む併用療法 Download PDF

Info

Publication number
JP2024516998A
JP2024516998A JP2023567923A JP2023567923A JP2024516998A JP 2024516998 A JP2024516998 A JP 2024516998A JP 2023567923 A JP2023567923 A JP 2023567923A JP 2023567923 A JP2023567923 A JP 2023567923A JP 2024516998 A JP2024516998 A JP 2024516998A
Authority
JP
Japan
Prior art keywords
inhibitor
egfr
cancer
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516998A5 (https=
Inventor
ショジャエイ，ファーボッド
エム． リコノ，ジル
グデノフ，ロバート
ギリングス，ミレイユ
Original Assignee
フヤバイオ インターナショナル，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フヤバイオ インターナショナル，エルエルシー filed Critical フヤバイオ インターナショナル，エルエルシー
Publication of JP2024516998A publication Critical patent/JP2024516998A/ja
Publication of JP2024516998A5 publication Critical patent/JP2024516998A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023567923A 2021-05-05 2022-05-04 Ｓｈｐ２阻害剤とｅｇｆｒチロシンキナーゼ阻害剤とを含む併用療法 Pending JP2024516998A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163184697P 2021-05-05 2021-05-05
US63/184,697 2021-05-05
US202263320991P 2022-03-17 2022-03-17
US63/320,991 2022-03-17
PCT/US2022/027693 WO2022235815A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2024516998A true JP2024516998A (ja) 2024-04-18
JP2024516998A5 JP2024516998A5 (https=) 2025-05-14

Family

ID=83932546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567923A Pending JP2024516998A (ja) 2021-05-05 2022-05-04 Ｓｈｐ２阻害剤とｅｇｆｒチロシンキナーゼ阻害剤とを含む併用療法

Country Status (8)

Country Link
US (1) US20220370456A1 (https=)
EP (1) EP4334317A4 (https=)
JP (1) JP2024516998A (https=)
AU (1) AU2022270106A1 (https=)
CA (1) CA3217092A1 (https=)
IL (1) IL308225A (https=)
MX (1) MX2023012929A (https=)
WO (1) WO2022235815A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216706A1 (en) * 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
CA3048340A1 (en) * 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
US11033547B2 (en) * 2019-03-07 2021-06-15 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as SHP2 antagonists
JP2024505680A (ja) * 2021-02-05 2024-02-07 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法
IL308222A (en) * 2021-05-05 2024-01-01 Huyabio Int Llc Combination therapies that include SHP2 inhibitors and PD-1 inhibitors
JP2024516997A (ja) * 2021-05-05 2024-04-18 フヤバイオ インターナショナル，エルエルシー Ｓｈｐ２阻害剤単独療法およびその使用

Also Published As

Publication number Publication date
IL308225A (en) 2024-01-01
CA3217092A1 (en) 2022-11-10
WO2022235815A1 (en) 2022-11-10
EP4334317A1 (en) 2024-03-13
EP4334317A4 (en) 2025-03-05
AU2022270106A1 (en) 2023-12-14
MX2023012929A (es) 2023-11-13
US20220370456A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
US12390469B2 (en) SHP2 inhibitor monotherapy and uses thereof
JP7075928B2 (ja) フェニレート誘導体、調製及び医薬組成物及び使用
US20100104567A1 (en) Pharmaceutical composition
WO2006074428A2 (en) Cxcr4 antagonists for the treatment of medical disorders
EA032509B1 (ru) Замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
TW201819380A (zh) 作為抗病毒劑之稠合四環吡啶酮化合物
JP7660801B2 (ja) 脳透過性ｂｔｋ又はｈｅｒ２阻害剤としての化合物およびその製造方法と応用
TWI757726B (zh) 4(1h)-奎諾酮衍生物及其用途
US12097203B2 (en) Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors
JP2021514955A (ja) プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法
US20240182429A1 (en) Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use
EP4313052A1 (en) Alk-5 inhibitors and uses thereof
CN117677619A (zh) 包含shp2抑制剂和pd-1抑制剂的联合疗法
JP2024516998A (ja) Ｓｈｐ２阻害剤とｅｇｆｒチロシンキナーゼ阻害剤とを含む併用療法
CN117642398A (zh) 包含shp2抑制剂和egfr酪氨酸激酶抑制剂的联合疗法
HK40108830A (zh) 包含shp2抑制剂和egfr酪氨酸激酶抑制剂的联合疗法
CN119031911A (zh) 癌的治疗或预防用药物
HK40108828A (zh) 包含shp2抑制剂和pd-1抑制剂的联合疗法
CN117881657A (zh) 苯基-氨磺酰基-苯甲酸衍生物作为erap1调节剂
HK40108829A (zh) Shp2抑制剂单一疗法及其用途
CN101137379B (zh) 用于治疗医学病症的cxcr4拮抗剂
KR20230072446A (ko) 암의 치료를 위한 인돌아민 2,3-디옥시게나아제 저해제와 면역체크포인트 억제제의 상승적 조합
TW202442228A (zh) 作為tyk2抑制劑的雜環化合物及合成與應用
JP2025539347A (ja) Ｋｒａｓ阻害剤とｓｈｐ２阻害剤とを含む併用療法
TW202214594A (zh) 含硫異吲哚啉類衍生物、其製備方法及其在醫藥上的應用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260416